Compare Merck & Co., Inc. (MRK) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Global X Defense Tech ETF — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Global X Defense Tech ETF trades at $60.14. The key difference: Merck & Co., Inc. pays a 2.73% dividend while Global X Defense Tech ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SHLD | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | Sector/Thematic |
52-Week High | $129.52 | $78.02 |
52-Week Low | $77.60 | $58.20 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
SHLD trades at $60.03, down slightly by 0.05% with a bearish technical signal from moving averages. The ETF offers exposure to global defense technology companies amid rising military spending trends. Recent news highlights institutional buying interest and geopolitical tailwinds supporting the sector's growth outlook.
The defense technology theme benefits from increased global budgets, but SHLD faces competition from other defense ETFs and valuation concerns. Near-term technical support at $59 could stabilize declines, while resistance at $61 may cap upside. Risks include political shifts and execution challenges among holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
